We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
The effect on erectile function of<sup>103</sup>palladium implantation for localized prostate cancer.
- Authors
Ponholzer, Anton; Oismüller, Renée; Somay, Canatay; Büchler, Felix; Maier, Ulrich; Hawliczek, Robert; Rauchenwald, Michael; Madersbacher, Stephan
- Abstract
To determine in a prospective study the effect on erectile function of103Pd brachytherapy for localized prostate cancer, using a validated questionnaire.Between July 1999 and April 2003, 113 men with localized prostate cancer were treated by permanent implantation of103Pd seeds, of whom 78 with a follow-up of 30 months were included in this study. No patient received supplemental external beam radiation therapy. At baseline and 3-month intervals, erectile function (EF) was assessed by the EF domain score of the International Index of Erectile Function-15 (IIEF-15); 77% received (neo)adjuvant antiandrogen therapy for up to 3 months.At baseline, 27 (35%) patients had no erectile dysfunction (ED; EF domain score 26–30), 24 (31%) had mild/moderate ED (score 11–25) and 27 (35%) severe ED (score 6–10). The mean EF domain score decreased from 17 to 12 (P < 0.001) after 30 months. Overall, 52 men (67%, including those with severe ED at baseline) remained in the same ED category at 30 months after therapy as before, 12 (15%) deteriorated by one category, 14 (18%) by two or more, and no patient improved. Of the 27 patients fully potent (score 26–30) at baseline, 37% remained so after 30 months, 19% developed mild and the remaining 44% moderate/severe ED. In a multivariate analysis, neither age nor preoperative prostate-specific antigen level, prostate volume, D90, hormonal treatment, diabetes, smoking or hypertension were predictive of preserving potency (P > 0.05).There was a high prevalence of pre-existing ED in these men; 57% of men fully potent or with mild ED at baseline remained so 30 months after brachytherapy.
- Subjects
PALLADIUM; PLATINUM group; PROSTATE cancer; THERAPEUTICS; MEN'S health; IMMUNOLOGICAL adjuvants
- Publication
BJU International, 2005, Vol 95, Issue 6, p847
- ISSN
1464-4096
- Publication type
Article
- DOI
10.1111/j.1464-410X.2005.05414.x